Thymosin Beta-4
Also known as: TB4, Tβ4
Thymosin beta-4 sequesters monomeric G-actin to regulate the actin cytoskeleton, enabling cell migration, angiogenesis and tissue repair, with an anti-fibrotic Ac-SDKP fragment.
- Drug class
- Endogenous actin-sequestering peptide (beta-thymosin family)
- Primary targets
- G-actin
- Dose reference
- No established therapeutic dose; phase 1 IV studies used 42-1260 mg
- Half-life
- Short, dose-dependent ~1-2 hours (IV)
- Developer / origin
- RegeneRx
- Reference year
- 1981
- Evidence score
- 3/5 - Mechanistically strong, clinically narrow
Mechanistically strong, clinically narrow
Thymosin beta-4 is a genuine endogenous actin-sequestering peptide with angiogenic and anti-fibrotic biology. Human evidence is strongest for topical/ocular use; systemic injectable use for recovery is unproven.
Limited human pharmacology or small clinical evidence.
Evidence basis
- Phase 3 ophthalmic program (RGN-259) in dry eye and neurotrophic keratopathy
- Preclinical dermal wound and cardiac repair data
- Phase 1 IV tolerability to 1260 mg with no dose-limiting toxicity
- No FDA-approved drug; consumer products often supply the TB-500 fragment
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
Thymosin Beta-4 guides
Read the matching guide or adjacent research pages for more context.
Peptide calculators
Use calculators for concentration, unit conversion and repeated-dose accumulation math.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
BPC-157
Body Protection Compound-157
Derived from human gastric juice. Animal models suggest effects on angiogenesis, tendon healing and GI repair; human clinical data is very limited.
TB-500
Thymosin Beta-4 fragment
Synthetic fragment of thymosin β4 studied in animal models for cell migration, angiogenesis and tissue repair. No approved human indication.
VIP (Vasoactive Intestinal Peptide)
Aviptadil
VIP activates VPAC1 and VPAC2 receptors, raising intracellular cyclic AMP to drive vasodilation, smooth-muscle relaxation and immune modulation.
Category hub
Open the category page for the full comparison table and FAQ.